Contact
searchSearch
HMP Global
Login

Myeloproliferative Neoplasms Specialty Channel

Myeloproliferative Neoplasms
Specialty Channel
News
Eltrombopag and Cyclosporin A Demonstrate Beneficial Outcomes as Frontline Treatment for Patients With Severe Aplastic Anemia
03/18/2024

Jordan Kadish

Jordan Kadish
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR...
03/18/2024
Oncology
Anthony Hunter, MD
Videos
Choosing Interferon Treatment for Patients With Myeloproliferative Neoplasms
10/16/2023
Anthony Hunter, MD, discusses the role of interferon regimens for patients with myeloproliferative neoplasms, including polycythemia vera and essential thrombocythemia.
Anthony Hunter, MD, discusses the role of interferon regimens for patients with myeloproliferative neoplasms, including polycythemia vera and essential thrombocythemia.
Anthony Hunter, MD, discusses...
10/16/2023
Oncology
Quiz
Hydroxyurea Dosage and Management for Patients With PV
09/25/2023
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a...
09/25/2023
Oncology
News
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio as Potential Minor Criteria for Polycythemia Vera Diagnosis
08/22/2023
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio...
08/22/2023
Oncology
News
Optimizing Hydroxyurea Management Among Patients With Polycythemia Vera
08/09/2023
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea...
08/09/2023
Oncology
News
Alternative Dosing Regimen of Ropeginterferon Alfa-2b Demonstrates High Efficacy, Tolerability Among Patients With Polycythemia Vera
07/14/2023
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of...
07/14/2023
Oncology
News
Ruxolitinib Treatment Effective, Safe for Patients With Newly Diagnosed Polycythemia Vera
05/05/2023
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to...
05/05/2023
Oncology
John Mascarenhas, MD
Videos
Recent Advancements in Clinical Development for the Treatment of Myelofibrosis
05/04/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies conference, New York, John Mascarenhas, MD, discussed recent advancements in clinical developments for the treatment of myeloproliferative neoplasms, specifically myelofibrosis,...
At the 2023 Great Debates & Updates in Hematologic Malignancies conference, New York, John Mascarenhas, MD, discussed recent advancements in clinical developments for the treatment of myeloproliferative neoplasms, specifically myelofibrosis,...
At the 2023 Great Debates &...
05/04/2023
Oncology
Claire Harrison, MD
Videos
Second-Line Therapy for Patients With Polycythemia Vera: A Review of Data on Ruxolitinib
05/04/2023
In the final part of an expert roundtable series, Claire Harrison, MD, leads a panel discussion reviewing data on second-line therapies, particularly ruxolitinib, for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and...
In the final part of an expert roundtable series, Claire Harrison, MD, leads a panel discussion reviewing data on second-line therapies, particularly ruxolitinib, for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and...
In the final part of an expert...
05/04/2023
Oncology
Claire Harrison, MD
Videos
How to Determine When First-Line Therapy for Polycythemia Vera is Failing
05/04/2023
In part 3 of an expert roundtable series, Claire Harrison, MD, leads a panel discussion on how to determine when first-line polycythemia vera therapy is failing with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 3 of an expert roundtable series, Claire Harrison, MD, leads a panel discussion on how to determine when first-line polycythemia vera therapy is failing with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 3 of an expert...
05/04/2023
Oncology
Claire Harrison, MD
Videos
Aims of Treatment and Choice of First-Line Therapy for Patients With Polycythemia Vera
05/04/2023
In part 2 of an expert roundtable series, Claire Harrison, MD, leads a discussion on the aims of treatment and choice of first-line therapy for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 2 of an expert roundtable series, Claire Harrison, MD, leads a discussion on the aims of treatment and choice of first-line therapy for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 2 of an expert...
05/04/2023
Oncology

News

News
Eltrombopag and Cyclosporin A Demonstrate Beneficial Outcomes as Frontline Treatment for Patients With Severe Aplastic Anemia
03/18/2024

Jordan Kadish

Jordan Kadish
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR...
03/18/2024
Oncology
News
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio as Potential Minor Criteria for Polycythemia Vera Diagnosis
08/22/2023
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio...
08/22/2023
Oncology
News
Optimizing Hydroxyurea Management Among Patients With Polycythemia Vera
08/09/2023
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea...
08/09/2023
Oncology
News
Alternative Dosing Regimen of Ropeginterferon Alfa-2b Demonstrates High Efficacy, Tolerability Among Patients With Polycythemia Vera
07/14/2023
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of...
07/14/2023
Oncology
News
Ruxolitinib Treatment Effective, Safe for Patients With Newly Diagnosed Polycythemia Vera
05/05/2023
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to...
05/05/2023
Oncology
News
Momelotinib Improved Anemia Measures, Spleen Response, and Overall Safety Among Patients With Myelofibrosis
04/21/2023
According to a phase 3 trial, momelotinib, a first-class JAK1 and JAK2 inhibitor, improved anemia measures, spleen response, and overall safety among patients with myelofibrosis compared to other JAK inhibitors.
According to a phase 3 trial, momelotinib, a first-class JAK1 and JAK2 inhibitor, improved anemia measures, spleen response, and overall safety among patients with myelofibrosis compared to other JAK inhibitors.
According to a phase 3 trial,...
04/21/2023
Oncology
News
Low-Intensity Regimens for Sickle Cell Disease Transplantation Associated With Risk of Secondary Neoplasms
03/13/2023
Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.
Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.
Low-intensity regimens for...
03/13/2023
Oncology
Conference Coverage
Ropeginterferon Alfa-2b Yielded Higher Hematologic and Molecular Response Rates Among Patients With Low-Risk vs High-Risk Polycythemia Vera
02/27/2023
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that...
02/27/2023
Oncology
News
Increased Likelihood of Blood Clots in Patients With Non-Proliferative CBC Thrombosis Myeloproliferative Neoplasms
02/27/2023
A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...
A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...
A study found that patients with...
02/27/2023
Oncology
News
Cytoreduction and JAK Inhibitors Associated With Fewer Thrombotic Events in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis
09/30/2022
Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombotic events in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombotic events in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
Both conventional cytoreduction...
09/30/2022
Oncology

Interactive Features

Quiz
Hydroxyurea Dosage and Management for Patients With PV
09/25/2023
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a...
09/25/2023
Oncology
Quiz
Cytoreduction and JAK Inhibitors in Patients With Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis
11/30/2022
True or False: Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
True or False: Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
True or False: Both conventional...
11/30/2022
Oncology
Quiz
Quiz: Cytogenic Response Rate of Pemigatinib in Myeloid/Lymphoid Neoplasms Harboring an FGFR1 Arrangement
09/02/2022
The FDA granted approval to pemigatinib to treat adult patients with relapsed or refractory myeloid/lymphoid neoplasms and an FGFR1 rearrangement. In the phase 2 trial which led to the approval, what was the complete cytogenetic response rate...
The FDA granted approval to pemigatinib to treat adult patients with relapsed or refractory myeloid/lymphoid neoplasms and an FGFR1 rearrangement. In the phase 2 trial which led to the approval, what was the complete cytogenetic response rate...
The FDA granted approval to...
09/02/2022
Oncology
idea
Test Your Knowledge
Quiz: Do Antiplatelet, Anticoagulation Therapies Increase Bleeding Risk for MPNs?
02/01/2022
True or false: A retrospective study found antiplatelet and anticoagulation therapies do not increase the risk of bleeding events in patients with MPNs.
True or false: A retrospective study found antiplatelet and anticoagulation therapies do not increase the risk of bleeding events in patients with MPNs.
True or false: A retrospective...
02/01/2022
Oncology
Question marks
Quiz
Quiz: Sotatercept for Anemic Patients With MPN-Associated MF
01/20/2022
True or false: A phase 2 study found sotatercept to be unsafe and ineffective for anemic patients with MPN-associated MF.
True or false: A phase 2 study found sotatercept to be unsafe and ineffective for anemic patients with MPN-associated MF.
True or false: A phase 2 study...
01/20/2022
Oncology
writing
Test Your Knowledge
Quiz: Pulmonary Hypertension in Patients With MPNs
01/06/2022
True or false: Findings from a single-center retrospective study investigated the prognostic implication of pulmonary hypertension (PH) in a high-risk MPNs patient population and found PH is associated with worse outcomes.
True or false: Findings from a single-center retrospective study investigated the prognostic implication of pulmonary hypertension (PH) in a high-risk MPNs patient population and found PH is associated with worse outcomes.
True or false: Findings from a...
01/06/2022
Oncology
?
Test Your Knowledge
Quiz: Are DOACs Associated With High Bleeding Rates in MPNs?
12/17/2021
True or false: DOAC’s are associated with high bleeding rates in patients with MPNs.
True or false: DOAC’s are associated with high bleeding rates in patients with MPNs.
True or false: DOAC’s are...
12/17/2021
Oncology
Computer
Test Your Knowledge
Quiz: Does This Inhibitor Therapy Yield Safety in Portal Hypertension MPNs?
12/16/2021
True or false: JAK inhibitor therapy is safe and effective in patients with MPNs complicated by PT without underlying ST.
True or false: JAK inhibitor therapy is safe and effective in patients with MPNs complicated by PT without underlying ST.
True or false: JAK inhibitor...
12/16/2021
Oncology
Test Your Knowledge
Quiz: Mutation Identified as High-Risk Bleeding Factor in MPN
11/29/2021
Which of the following mutations is associated with a higher risk of bleeding in adult patients with MPN?
Which of the following mutations is associated with a higher risk of bleeding in adult patients with MPN?
Which of the following mutations...
11/29/2021
Oncology
qq
Test Your Knowledge
Quiz: Which Mutation Was Identified as High-Risk Bleeding Factor in MPN?
11/11/2021
Which of the following mutations was identified as a high-risk bleeding factor in MPN?
Which of the following mutations was identified as a high-risk bleeding factor in MPN?
Which of the following mutations...
11/11/2021
Oncology

Recent News

News
Eltrombopag and Cyclosporin A Demonstrate Beneficial Outcomes as Frontline Treatment for Patients With Severe Aplastic Anemia
03/18/2024

Jordan Kadish

Jordan Kadish
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR...
03/18/2024
Oncology
News
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio as Potential Minor Criteria for Polycythemia Vera Diagnosis
08/22/2023
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio...
08/22/2023
Oncology
News
Optimizing Hydroxyurea Management Among Patients With Polycythemia Vera
08/09/2023
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea...
08/09/2023
Oncology
News
Alternative Dosing Regimen of Ropeginterferon Alfa-2b Demonstrates High Efficacy, Tolerability Among Patients With Polycythemia Vera
07/14/2023
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of...
07/14/2023
Oncology
News
Ruxolitinib Treatment Effective, Safe for Patients With Newly Diagnosed Polycythemia Vera
05/05/2023
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to...
05/05/2023
Oncology
News
Momelotinib Improved Anemia Measures, Spleen Response, and Overall Safety Among Patients With Myelofibrosis
04/21/2023
According to a phase 3 trial, momelotinib, a first-class JAK1 and JAK2 inhibitor, improved anemia measures, spleen response, and overall safety among patients with myelofibrosis compared to other JAK inhibitors.
According to a phase 3 trial, momelotinib, a first-class JAK1 and JAK2 inhibitor, improved anemia measures, spleen response, and overall safety among patients with myelofibrosis compared to other JAK inhibitors.
According to a phase 3 trial,...
04/21/2023
Oncology
News
Low-Intensity Regimens for Sickle Cell Disease Transplantation Associated With Risk of Secondary Neoplasms
03/13/2023
Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.
Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.
Low-intensity regimens for...
03/13/2023
Oncology
Conference Coverage
Ropeginterferon Alfa-2b Yielded Higher Hematologic and Molecular Response Rates Among Patients With Low-Risk vs High-Risk Polycythemia Vera
02/27/2023
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that...
02/27/2023
Oncology
News
Increased Likelihood of Blood Clots in Patients With Non-Proliferative CBC Thrombosis Myeloproliferative Neoplasms
02/27/2023
A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...
A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...
A study found that patients with...
02/27/2023
Oncology
News
Cytoreduction and JAK Inhibitors Associated With Fewer Thrombotic Events in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis
09/30/2022
Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombotic events in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombotic events in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
Both conventional cytoreduction...
09/30/2022
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use